USPTO Patent Grant: RNA-based Adjuvant for Vaccines

The USPTO has granted patent US12582711B2 to IMMUNESURE LLC for an RNA-based adjuvant composition designed to enhance immune responses to vaccines and therapeutics. The patent describes antisense inhibitor compositions targeting IL-10 or IL-10RA genes.

USPTO Patent Grant: T-cell responses to cancer antigens

The USPTO has granted patent US12582709B2 to The Regents of the University of California for a novel method of inducing long-lived immune responses to cancer and infectious-disease antigens. The patent covers recombinant polynucleotides and their use in pharmaceutical compositions and host cells.

USPTO Patent US12582708B2: Recombinant Influenza Viruses

The USPTO has granted patent US12582708B2 for a novel recombinant influenza virus engineered to express an interferon-beta gene. This patent, assigned to I.D.BIO., aims to enhance antiviral action by introducing a foreign gene into the NS1 gene of the influenza virus.

USPTO Patent US12582699B2: Lymphocyte Immunotherapy Compositions

The USPTO has granted patent US12582699B2 to the Provincial Health Services Authority for lymphocyte immunotherapy compositions and methods. The patent covers lymphocytes with suppressed autophagy genes, useful for targeting tumor-specific antigens in therapies like CAR-T and TCR-T.

USPTO Patent Grant: Skin Wound Treatment Compositions and Methods

The USPTO has granted patent US12582684B2 to Krystal Biotech, Inc. for compositions and methods related to the treatment of skin wounds, disorders, and diseases. The patent covers polynucleotides designed to enhance specific protein levels for therapeutic relief, particularly for conditions like epidermolysis bullosa.

USPTO Patent Grant: Pharmaceutical Composition for Skin Disease

The USPTO has granted a patent (US12582680B2) to RIKEN for a pharmaceutical composition derived from ampicillin-sensitive bacteria to treat skin diseases. The patent covers bacterial cells, culture supernatants, extracts, and metabolites as active components.

Sumitomo Chemical Patent: Retinal Tissue Production Method

The USPTO has granted Sumitomo Chemical Company, Limited a patent (US12582677B2) for a method of producing retinal tissue. The method involves culturing pluripotent stem cells under specific serum-free and serum-containing conditions. This patent covers methods for producing optic-cup-like structures, retinal pigment epithelium, and retinal layer-specific neural cells.

Arrowhead Pharmaceuticals Patent for AATD Treatment

The USPTO has granted Arrowhead Pharmaceuticals, Inc. a patent (US12582668B2) for methods of treating alpha-1 antitrypsin deficiency (AATD) using pharmaceutical compositions containing AAT RNAi agents. The patent filing date was June 5, 2020, and it is scheduled to be granted on March 24, 2026.

USPTO Patent Grant: Method for producing transplantable oral mucosa tissue

The USPTO has granted patent US12582750B2 to MUKOCELL GMBH for a method of producing transplantable oral mucosa tissue. This patent covers the use of specific markers to identify suitable oral mucosa for autologous grafts, particularly for urethral reconstruction or cornea implantation.

USPTO Patent Grant: AAV vectors for Schwann cell diseases

The USPTO has granted patent US12582725B2 for AAV vectors with a myelin protein zero promoter, designed for treating Schwann cell-associated diseases like Charcot-Marie-Tooth disease. The patent was assigned to The Cyprus Foundation for Muscular Dystrophy Research.